The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1529
September 11, 2017
View Complete Issue         Table of Contents 2019 
Deflazacort (Emflaza) for Duchenne Muscular Dystrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Deflazacort (Emflaza) for Duchenne Muscular Dystrophy
September 11, 2017 (Issue: 1529)
Deflazacort (Emflaza – PTC Therapeutics), an oral corticosteroid, has been approved by the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients ≥5 years old. It has been available outside the US for many years. Deflazacort is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Deflazacort (Emflaza) for Duchenne Muscular Dystrophy
Article code: 1529d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.